Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 185,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were bought at an average price of $3.83 per share, with a total value of $708,550.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $11,754,082.33. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, February 7th, Phillip Md Et Al Frost bought 78,000 shares of Opko Health stock. The shares were bought at an average price of $4.22 per share, with a total value of $329,160.00.
  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were bought at an average price of $4.14 per share, with a total value of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were bought at an average price of $4.30 per share, with a total value of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The shares were bought at an average price of $4.47 per share, with a total value of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were bought at an average price of $4.90 per share, with a total value of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were bought at an average price of $4.89 per share, with a total value of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were bought at an average price of $4.40 per share, with a total value of $440,000.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at $3.88 on Monday. The stock has a market cap of $2,170.00, a price-to-earnings ratio of -20.42 and a beta of 1.42. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $8.92.

Several equities analysts recently commented on OPK shares. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, BidaskClub cut shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $13.34.

A number of institutional investors have recently made changes to their positions in OPK. Prudential Financial Inc. increased its holdings in Opko Health by 6.1% in the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 1,400 shares during the period. Alliancebernstein L.P. increased its holdings in Opko Health by 18.6% in the 2nd quarter. Alliancebernstein L.P. now owns 213,324 shares of the biotechnology company’s stock valued at $1,404,000 after buying an additional 33,400 shares during the period. Teachers Advisors LLC increased its holdings in Opko Health by 17.5% in the 2nd quarter. Teachers Advisors LLC now owns 476,222 shares of the biotechnology company’s stock valued at $3,134,000 after buying an additional 70,971 shares during the period. Ameriprise Financial Inc. increased its holdings in Opko Health by 1.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 53,788 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 896 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in Opko Health by 8.5% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 224,668 shares of the biotechnology company’s stock valued at $1,478,000 after buying an additional 17,541 shares during the period. 22.68% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Opko Health Inc. (OPK) CEO Acquires 185,000 Shares of Stock” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/02/12/insider-buying-opko-health-inc-opk-ceo-acquires-185000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.